Small molecules, big impact: 20 years of targeted therapy in oncology
The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …
have led to the development of small molecule inhibitors as a major therapeutic class for …
Targeting BCL-2 regulated apoptosis in cancer
KJ Campbell, SWG Tait - Open biology, 2018 - royalsocietypublishing.org
The ability of a cell to undergo mitochondrial apoptosis is governed by pro-and anti-
apoptotic members of the BCL-2 protein family. The equilibrium of pro-versus anti-apoptotic …
apoptotic members of the BCL-2 protein family. The equilibrium of pro-versus anti-apoptotic …
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
AH Wei, P Montesinos, V Ivanov… - Blood, The Journal …, 2020 - ashpublications.org
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study
AH Wei, SA Strickland Jr, JZ Hou, W Fiedler… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma
Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in
multiple myeloma (MM) cells, particularly in those harboring t (11; 14), which express high …
multiple myeloma (MM) cells, particularly in those harboring t (11; 14), which express high …
Prognostic and predictive biomarker developments in multiple myeloma
CT Wallington-Beddoe, RL Mynott - Journal of hematology & oncology, 2021 - Springer
New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …
decision-making, or prediction, are needed since patients are currently managed in a similar …
BH3-mimetic drugs: blazing the trail for new cancer medicines
Defects in apoptotic cell death can promote cancer and impair responses of malignant cells
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by kee** the cell …
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by kee** the cell …
BCL2 and MCL1 inhibitors for hematologic malignancies
BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …
hematologic cancers and play important roles in their biology either through dysregulation or …
The proteasome and proteasome inhibitors in multiple myeloma
S Gandolfi, JP Laubach, T Hideshima… - Cancer and Metastasis …, 2017 - Springer
Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …
the treatment of multiple myeloma in the past two decades, and now form one of the …
Drug resistance in multiple myeloma
Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …